Bio-Rad Laboratories (NYSE:BIO) Releases Earnings Results, Beats Expectations By $0.81 EPS

Bio-Rad Laboratories (NYSE:BIO - Get Free Report) released its quarterly earnings data on Thursday. The medical research company reported $2.54 earnings per share for the quarter, topping the consensus estimate of $1.73 by $0.81, Zacks reports. Bio-Rad Laboratories had a negative net margin of 71.86% and a positive return on equity of 3.90%. The firm had revenue of $585.40 million for the quarter, compared to analyst estimates of $573.01 million. During the same quarter in the prior year, the business earned $2.30 earnings per share. Bio-Rad Laboratories's quarterly revenue was down 4.2% on a year-over-year basis. Bio-Rad Laboratories updated its FY 2025 guidance to EPS.

Bio-Rad Laboratories Price Performance

NYSE:BIO traded down $3.60 during midday trading on Friday, hitting $236.83. 697,416 shares of the stock were exchanged, compared to its average volume of 320,682. The company has a market capitalization of $6.63 billion, a price-to-earnings ratio of -3.64 and a beta of 1.12. The company has a current ratio of 6.48, a quick ratio of 4.85 and a debt-to-equity ratio of 0.18. Bio-Rad Laboratories has a one year low of $215.38 and a one year high of $387.99. The business has a 50-day moving average price of $246.93 and a two-hundred day moving average price of $305.12.

Analysts Set New Price Targets

A number of research analysts recently commented on the company. UBS Group lowered their price objective on Bio-Rad Laboratories from $355.00 to $310.00 and set a "buy" rating for the company in a research note on Friday. Citigroup dropped their price objective on shares of Bio-Rad Laboratories from $400.00 to $350.00 and set a "buy" rating on the stock in a report on Friday. Wells Fargo & Company reduced their target price on shares of Bio-Rad Laboratories from $320.00 to $270.00 and set an "equal weight" rating for the company in a research note on Thursday, April 17th. StockNews.com lowered shares of Bio-Rad Laboratories from a "buy" rating to a "hold" rating in a research note on Monday, February 17th. Finally, Royal Bank of Canada decreased their price objective on Bio-Rad Laboratories from $409.00 to $392.00 and set an "outperform" rating for the company in a report on Friday. Three equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company's stock. According to data from MarketBeat, Bio-Rad Laboratories presently has an average rating of "Moderate Buy" and a consensus price target of $327.40.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.